World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
81
Citations
28650
World Ranking
16489
National Ranking
1507

John R. Kirwan publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John R. Kirwan sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 432 publications — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

John R. Kirwan D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John R. Kirwan sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 81 D-Index — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Disease
  • Surgery

His primary areas of study are Physical therapy, Rheumatoid arthritis, Internal medicine, Rheumatology and MEDLINE. John R. Kirwan has included themes like Osteoarthritis, Clinical trial, Patient satisfaction and Psychological intervention in his Physical therapy study. His research in Rheumatoid arthritis intersects with topics in Inflammation, Severity of illness, Health assessment and Arthritis.

His Internal medicine research is multidisciplinary, incorporating perspectives in Placebo and Surgery. His Rheumatology research incorporates themes from Alternative medicine, Necrosis, Family medicine and Health professionals. He interconnects Rheumatism and Evidence-based practice in the investigation of issues within MEDLINE.

His most cited work include:

  • American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials (993 citations)
  • Recommendations for a core set of outcome measures for future Phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III (634 citations)
  • Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0 (484 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Rheumatoid arthritis, Physical therapy, Internal medicine, Rheumatology and Clinical trial. His Rheumatoid arthritis study incorporates themes from Prednisolone, Glucocorticoid, Disease and Arthritis. His work carried out in the field of Physical therapy brings together such families of science as Osteoarthritis, Alternative medicine, Patient satisfaction, MEDLINE and Randomized controlled trial.

His Osteoarthritis study combines topics in areas such as Knee Joint and Radiography. His work deals with themes such as Endocrinology and Surgery, which intersect with Internal medicine. John R. Kirwan regularly ties together related areas like Severity of illness in his Clinical trial studies.

He most often published in these fields:

  • Rheumatoid arthritis (45.93%)
  • Physical therapy (40.74%)
  • Internal medicine (34.57%)

What were the highlights of his more recent work (between 2012-2020)?

  • Physical therapy (40.74%)
  • Rheumatoid arthritis (45.93%)
  • Internal medicine (34.57%)

In recent papers he was focusing on the following fields of study:

John R. Kirwan mostly deals with Physical therapy, Rheumatoid arthritis, Internal medicine, Rheumatology and Randomized controlled trial. The various areas that he examines in his Physical therapy study include Psychological intervention, Self-management, Clinical trial, Arthritis and Intervention. His study in Clinical trial is interdisciplinary in nature, drawing from both Visual analogue scale, Context, Family medicine and Scope.

The Rheumatoid arthritis study combines topics in areas such as Alternative medicine, Disease, Coping, Clinical psychology and Prednisone. His Internal medicine study integrates concerns from other disciplines, such as Immunology and Outcomes research. His work in Randomized controlled trial tackles topics such as Mood which are related to areas like Feeling.

Between 2012 and 2020, his most popular works were:

  • Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0 (484 citations)
  • EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases (158 citations)
  • Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2) (118 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Disease
  • Surgery

His main research concerns Physical therapy, Internal medicine, Rheumatology, Outcome and Medical education. His Physical therapy research is multidisciplinary, incorporating elements of Clinical trial, Quality of life, Systematic review, Rheumatoid arthritis and Severity of illness. His Rheumatoid arthritis research includes elements of Rating scale, Disease, Coping and Outcomes research.

His study in Morning and Prednisone is carried out as part of his studies in Internal medicine. John R. Kirwan combines subjects such as Osteoarthritis, Context, Randomized controlled trial, Intention-to-treat analysis and Visual analogue scale with his study of Rheumatology. His studies in Medical education integrate themes in fields like Alternative medicine, Patient participation and Moderation.

Best Publications

  • American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

    David T. Felson;David T. Felson;Josef S. Smolen;George Wells;Bi Zhang

  • Recommendations for a core set of outcome measures for future Phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III

    Nicholas Bellamy;John Kirwan;Maarten Boers;Peter Brooks

  • Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0

    Maarten Boers;John R. Kirwan;George Wells;Dorcas Beaton

  • Determinants of disability in osteoarthritis of the knee.

    T. E. M. Mcalindon;C. Cooper;J. R. Kirwan;P. A. Dieppe

  • STANFORD HEALTH ASSESSMENT QUESTIONNAIRE MODIFIED TO ASSESS DISABILITY IN BRITISH PATIENTS WITH RHEUMATOID ARTHRITIS

    J. R. Kirwan;Jane S. Reeback

  • Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology

    F. Buttgereit;J.A. da Silva;M. Boers;G.R. Burmester

  • Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data

    J A P Da Silva;J W G Jacobs;J R Kirwan;M Boers

  • Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy.

    Paul Dieppe;Janet Cushnaghan;Philip Young;John Kirwan

  • EULAR evidence based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

    J. N. Hoes;J. W. G. Jacobs;M. Boers;D. Boumpas

  • Effects of glucocorticoids on radiological progression in rheumatoid arthritis.

    John R Kirwan;Johannes Wj Bijlsma;Maarten Boers;Beverley Shea

  • Patient education for adults with rheumatoid arthritis

    Robert P Riemsma;John R Kirwan;Erik Taal;Hans Jj Rasker

  • Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis.

    John R Kirwan;Patricia Minnock;Ade Adebajo;Barry Bresnihan

  • Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative

    L Gossec;S Paternotte;G J Aanerud;A Balanescu

  • Rheumatology outcomes: the patient's perspective.

    Alison Carr;Sarah Hewlett;Rod Hughes;Helene Mitchell

  • KNEE PAIN AND DISABILITY IN THE COMMUNITY

    T. E. McALINDON;C. Cooper;J. R. Kirwan;P. A. Dieppe

  • Non-pharmacological interventions for fatigue in rheumatoid arthritis

    Fiona Cramp;Sarah Hewlett;Celia Almeida;John R Kirwan

  • Patients and professionals as research partners: challenges, practicalities, and benefits.

    Sarah Hewlett;Marteen de Wit;Pam Richards;Enid Quest

  • EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases

    N Duru;M C van der Goes;J W G Jacobs;Tara Andrews

  • Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group.

    P Hickling;R K Jacoby;J R Kirwan

  • Quality of life measures

    A. J. Carr;P. W. Thompson;J. R. Kirwan

Frequent Co-Authors

Maarten Boers
Maarten Boers Vrije Universiteit Amsterdam
Peter Tugwell
Peter Tugwell University of Ottawa
Ernest Choy
Ernest Choy Cardiff University
Laure Gossec
Laure Gossec Sorbonne University
George A. Wells
George A. Wells University of Ottawa
Vibeke Strand
Vibeke Strand Stanford University
Peter Brooks
Peter Brooks University of Melbourne
Paul Dieppe
Paul Dieppe University of Exeter
Clifton O. Bingham
Clifton O. Bingham Johns Hopkins University
Maxime Dougados
Maxime Dougados Hôpital Cochin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degrees in healthcare can open the door to a rewarding medical career, offering flexibility and affordability. Many students start by completing the cheapest online nursing program to earn essential credentials without incurring hefty debt. These programs offer a strong foundation in patient care and make it easier to start working while studying further.

For those aiming to advance their careers, there are flexible pathways to higher degrees. Many working nurses consider earning a phd in nursing online programs to move into leadership, research, or education roles.

Registered nurses looking to upgrade their qualifications can review the average cost of rn to bsn programs online. These programs often suit working professionals and help open up doors to more specialized positions.

If you have a non-nursing bachelor’s degree but wish to enter the nursing field quickly, consider direct entry nurse practitioner programs for non-nurses online. These accelerated programs can fast-track your journey to becoming a nurse practitioner, expanding your career options and impact in healthcare.

Best Scientists Citing John R. Kirwan

Trending Scientists

Recently Published Articles